NAV

ST-101

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
ST-101
DrugBank Accession Number
DB12621
Background

ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.1

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Peptides
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • C/EBP Beta Antagonist ST101
  • D-Arginine, D-valyl-D-alanyl-D-α-glutamyl-D-alanyl-D-arginyl-D-α-glutamyl-D-α-glutamyl-D-leucyl-D-α-glutamyl-D-arginyl-D-leucyl-D-α-glutamyl-D-alanyl-D-arginyl-D-leucylglycyl-D-glutaminyl-D-alanyl-D-arginylglycyl-D-α-glutamyl-D-leucyl-D-lysyl-D-lys
  • H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine
  • ST-101 (D-AMINO ACID PEPTIDE)
  • ST101 (peptide)
External IDs
  • ST 101
  • ST101
  • ZSET-1446
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7TTT61784C
CAS number
887603-94-3

References

General References
  1. Papazoglou A, Arshaad MI, Henseler C, Daubner J, Broich K, Hescheler J, Ehninger D, Haenisch B, Weiergraber M: Ca(v)3 T-Type Voltage-Gated Ca(2+) Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance. Int J Mol Sci. 2022 Mar 22;23(7):3457. doi: 10.3390/ijms23073457. [Article]
PubChem Compound
10220323
PubChem Substance
347828833
ChemSpider
8395815
ChEMBL
CHEMBL4297437
ZINC
ZINC000001491487

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)2
2CompletedTreatmentEssential Tremor1
1, 2RecruitingTreatmentBrain Cancer / Breast Cancer / Glioblastoma Multiforme (GBM) / High Grade Glioma: Glioblastoma (GBM) / Metastatic Breast Cancer / Metastatic Melanoma / Metastatic Prostate Cancer / Newly diagnosed Glioblastoma Multiforme (GBM) / Prostate Cancer / Recurrent Glioblastoma / Recurrent Melanoma / Stage IV Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 23:15 / Updated at September 28, 2023 05:40